Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 44 Radiotherapy 16 Bevacizumab 9 Surgical Procedures, Operative 5 Carmustine 5 pembrolizumab 4 Lomustine 4 Drug Therapy 4 Sunitinib 3 Standard of Care 3 Radiation 3 Procarbazine 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Chlorotoxin 3 Carboplatin 3 Blood Specimen Collection 3 tislelizumab 2 fludarabine 2 camrelizumab 2 Radiosurgery 2 Neoadjuvant Therapy 2 Magnetic Resonance Spectroscopy 2 Hyperbaric Oxygenation 2 Ethanol 2 Cyclophosphamide 2 Chemotherapy, Adjuvant 2 CT-322 2 Bortezomib 2 Aminolevulinic Acid 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Glioblastoma × belinostat × Clear all

NCT02137759 2023-05-06

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Emory University

Phase 2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡